Nextech

18 Jul 19
VentureBeat
Series A Round Led by Vida Ventures and Omega Funds Company Platform Using Small Molecule Microarray (SMM) Technology has the Potential to Unlock Historically Undruggable Targets SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–July 18, 2019– Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced it has closed a $105 million Series A Preferred Stock financing. The financing was led by Vida Ventures, LLC and Omega Funds and included participation from Nextech, GV (formerly Google Ventures), Perceptive Advisors, Invus and Polaris Partners. This Series A round also included significant participation from Kronos’ President and Chief Executive Officer, Norbert Bischofberger, Ph.D. as well as members of the Board of Directors including Arie Belldegrun, M.D., FACS and John Martin, Ph.D. In conjunction with this financing, Jakob Loven, Ph.D., Partner at Nextech, will join the Board of Directors of Kronos Bio. Kronos’ Small Molecule Microarray platform (SMM) was built on more than a decade of research by its scientific founder, Angela Koehler, Ph.D., Associate Professor of Biological Engineering at the Massachusetts Institute of Technology. SMM is ideally suited for the rapid discovery of novel modulators or degraders of historically undruggable targets, such as transcription factors. Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity. SMM enables discovery of hits that act through a variety of mechanisms, including disruption of protein-protein or protein-DNA interactions, or indirect modulation of target protein activity by binding to co-factors or other protein complex members. “We are excited to have the continued support of high caliber investors who recognize the potential of Kronos’ technology and its team. This financing will help us advance two preclinical programs built upon hits identified from SMM screens, accelerate our research, and further expand the Kronos team in the Boston and San Francisco areas,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “We seek to challenge the historic belief that certain targets cannot be pursued. Our goal is to unlock new therapeutic approaches and bring treatments to areas with high unmet need.” Existing therapies target only a minority of the body’s proteins, which are well-structured and accessible to traditional small molecule approaches. The majority of proteins, however, are disordered or lack obvious binding pockets and have historically been considered undruggable. Kronos’ platform enables high-throughput screens of chemical libraries against such target proteins in a more physiologically relevant context to identify biologically active small molecules. “When we founded Kronos at Two River, we identified early on the need for support by investors who embrace cutting edge innovation,” said Joshua Kazam, a Kronos Board Member and a Director at Vida Ventures. “With this Series A round, we have expanded support with investors equally as passionate about funding scientific breakthroughs to impact how we treat some of the most challenging diseases we face today.” “Since our initial investment, we have been very excited about the opportunity to identify novel therapies provided by the Kronos platform: we believe this is a huge opportunity not just for investors but more importantly, for addressing unmet needs in hard-to-treat diseases,” said Otello Stampacchia, Ph.D., a Kronos Board Member and Founder and Managing Director of Omega Funds. “We are delighted to co-lead this milestone Series A financing and to be a part of the Kronos Bio team in this journey.” About Kronos Bio Kronos Bio, Inc. is dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets. We leverage deep capabilities in high-throughput small molecule microarrays, targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling. For more information, please visit www.kronosbio.com or follow the company on LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005191/en/ Kronos Bio Contact: Christopher WilfongChief Operating Officercmw@kronosbio.com Media Contact: Sheryl Seapysseapy@purecommunications.com Tel: (949) 903-4750
17 Jul 19
Fort Bissell Museum

Often during a sad time there can be special moments to brighten the darkest day and lighten the heaviest heart.  During July 2018 Richard Townley from Glade visited us with his daughter Linda who was here all the way from New Mexico.  During this visit he was extremely emotional seeing the civil war uniform of […]

17 Jul 19
Newsfile Corp.

New York, New York and Toronto, Ontario–(Newsfile Corp. – July 17, 2019) – NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”) is pleased to announce that it has entered into an agreement with Touchstone Home Products to ARitize™ its product line. NexTech AR and Touchstone Home Products, Inc. are launching […]

16 Jul 19
The Importance of Health

Global venture capital (VC) funding in digital health/health IT, including private equity and corporate venture capital, reach $5.1 billion in the first half of 2019, according to market research firm Mercom Capital. The 1H and Q2 2019 Digital Health (Healthcare IT) Funding and M&A Report reveals $5.1B in funding across 318 deals compared to $4.9B across 383 deals in 1H 2018. […]

15 Jul 19
Newsfile Corp.

New York, New York and Toronto, Ontario–(Newsfile Corp. – July 15, 2019) – NexTech AR Solutions Corp. (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”) a rapidly growing technology and emerging growth company focused on bringing augmented reality (“AR”) to the masses is pleased to announce that it has engaged the services of […]

12 Jul 19
Newsfile Corp.

CEO Evan Gappelberg Invests $857,000 New York, New York and Toronto, Ontario–(Newsfile Corp. – July 12, 2019) – NexTech AR Solutions Corp. (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”), a rapidly growing technology and emerging growth company focused on bringing augmented reality (“AR”) to the masses, is pleased to announce that it has […]

11 Jul 19
Business Industry Reports

This report provides in depth study of “Neurosurgery Software Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Neurosurgery Software Market report also provides an in-depth survey of key players in the market organization. Global Neurosurgery Software Market Overview: Neurosurgery Software Market report is a systematic research of the global […]

10 Jul 19
Newsfile Corp.

New York, New York and Toronto, Ontario–(Newsfile Corp. – July 10, 2019) – NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”) is pleased to announce that it has entered into an agreement with the Mr. Steak brand, most famous as the manufacturer of the Mr. Steak Grill, sold online and […]

09 Jul 19
Professional Industry Market Research

This recently published report examines the global Plastic Surgery Software market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Plastic Surgery Software market along […]

05 Jul 19
The Chestnut Post

The services provided by Health iPASS allow users to increase operating income while lowering the cost to collect patient payments. This partnership will enable our clients to provide a new consumer experience that facilitates transparency and trust. CHICAGO (PRWEB) July 05, 2019 Health iPASS, a patient check-in and revenue cycle management provider, today announces its […]

03 Jul 19
Newsfile Corp.

Budweiser #BudAR Augmented Reality Activation and Contest to Celebrate Bud Stage’s 25th Anniversary New York, New York and Toronto, Ontario–(Newsfile Corp. – July 3, 2019) – NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”) today announced its Budweiser contest for July is now live. Millions of fans can enter to […]

03 Jul 19
wiseguymarketresearch

Global Plastic Surgery Software Industry New Study On “2019-2025 Plastic Surgery Software Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database The report has covered the Global Plastic Surgery Software Industry and analyzed its potential to determine the statistics and information about the size of the market, share […]

29 Jun 19
Market Research Nest

Marketresearchnest.Com Adds “Global Dermatology Software Market Size, Status and Forecast 2019-2025” New Report To Its Research Database. The Report Spread across 94 Pages With Multiple Tables And Figures In It Dermatology software gives the flexibility to practice way according to customized workflow, freedom to focus on care and a comprehensive solution with anytime-anywhere access. In […]

26 Jun 19
Nextech Solutions

Pulses are one of the major sources of protein and energy. Pulses such as Bengal Gram/ Chick pea, pigeon pea, cow pea, Black Gram, Green Gram, Lentils, and Peas are some of the major pulses grown in India. The milling of pulses is done under three steps which are loosening of husk, dehusking and splitting of pulses.

25 Jun 19
Newsfile Corp.

New York, New York and Toronto, Ontario–(Newsfile Corp. – June 25, 2019) – NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”) is pleased to announce that it has entered into an agreement with BRNT Designs, a designer of architecturally unique accessories for creative and sophisticated cannabis users, to ARitize™ its entire […]

24 Jun 19
Newsfile Corp.

New York, New York and Toronto, Ontario–(Newsfile Corp. – June 24, 2019) – NexTech AR Solutions (OTCQB: NEXCF) (CSE: NTAR) )(FSE: N29) (the “Company” or “NexTech”) today announced that it’s CEO Evan Gappelberg will be on Yahoo Finance’s premier closing bell show The Final Round on Monday June 24th airing at 4:30pm. https://finance.yahoo.com/topic/finalround/ Watch here […]

20 Jun 19
The Chestnut Post

LOS ANGELES, June 20, 2019 /PRNewswire/ — ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it will attend and present at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held June 22-25, 2019, at the Anaheim Convention Center in Anaheim, California. ImaginAb will be presenting at the following sessions […]